Gold prices hit record high above $4,600/oz on Iran unrest, Fed indictment threat
Fed Chair Powell flags DOJ probe over interest rates; Trump denies involvement
’Sell America’ trade is back on as Powell subpoena rattles markets
Five things to watch in markets in the week ahead
Investing.com -- Shares inArgenx (EBR:ARGX)fell more than 3% in premarket trading Monday after the biotech group pre-released its fourth-quarter results, with sales broadly matching expectations.
The company reported fourth-quarter Vyvgart sales of $1.29 billion, slightly above company consensus of $1.26 billion and broadly in line with buyside expectations of around $1.3 billion.
UBS analysts said the print was effectively in line, noting that they expect “shares to be neutral to slightly negative given broadly in line (marginal miss) Vyvgart Q4 sales vs buyside expectation.”
Management also updated timelines across its late-stage pipeline, narrowing several key milestones. The Phase 3 study of Vyvgart in myositis is now due in the third quarter of 2026, while the Phase 3 trial of empasiprubart in MMN is expected in the fourth quarter of 2026.
Other programs, including Vyvgart in Graves disease and Sjogren’s, remain on track with previously communicated start windows, according to the company’s update.
UBS said that “key catalysts remain on track with a narrowed down timeline.” The bank said it will now look to upcoming medical meetings and further detail on pipeline assets beyond Vyvgart, including next-generation FcRn candidates and earlier-stage programs.
